Fig 1.
Participant disposition.
Table 1.
Age and gender of the study participants at inclusion, and vaccine doses received in 2005.
Table 2.
Booster history of all interviewed participants.
Fig 2.
Cumulative totals of non-boosted, discontinued, seroconverted, and boosted study participants at each year from enrollment through 4 years after PEP or PrEP vaccination in 2005.
Table 3.
Rabies virus-neutralizing antibody titers >0.5 IU/mL and GMTs at each follow up visit.
Fig 3.
Age and seroconversion rates (RFFIT titer >0.5 IU/mL) of study participants at each follow up visit.
Table 4.
GMTs (RFFIT) of the study participants by age group at inclusion and at 2, 3 and 4 years of follow-up after vaccination.
Fig 4.
Seroconversion rates (titer >0.5 IU/mL) and GMTs of male and female participants at each year of follow up (RFFIT assay).
Fig 5.
Seroconversion rates (RFFIT titer >0.5 IU/mL) of all non-boosted participants, and the non-boosted participants receiving PEP or PrEP vaccination in 2005.
Fig 6.
GMT (RFFIT) of all non-boosted participants, and the non-boosted participants receiving PEP or PrEP vaccination in 2005.
Table 5.
Correlation between FAVN and RFFIT/ELISA techniques in the non-boosted population.
Table 6.
Correlation between FAVN and RFFIT/ELISA techniques in the boosted population.
Table 7.
Correlation between RFFIT and ELISA assay results in the non-boosted study population.